UNSPSC 51422203: Rimexolone

This classification denotes a therapeutic glucocorticoid with the molecular formula C24H34O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O7M2E4264D, chemically known as 11beta-hydroxy-16alpha,17alpha-dimethyl-17-propionylandrosta-1,4-dien-3-one but generally known as rimexolone, which bears US NIH Compound Identifier 39507. European Medicines Agency schedules Rimexolone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10323MIG.

UNSPSC 51422203 Rimexolone is a Commodity code, but the recent state and local opportunities tagged under it do not involve rimexolone—an ophthalmic corticosteroid—at all. Seminole County, Florida solicited naloxone and drug deactivation systems through IFB 60459723LAS (due Jul 26, 2023), and the Texas Health and Human Services Commission issued an RFI for direct-to-manufacturer prescription fulfillment capabilities (HHS0017013, posted Apr 3, 2026). Neither procurement aligns with the code's nominal pharmaceutical scope. The mismatch suggests either miscoding at source or that the code carries little relevant recent activity under its stated definition.

The Seminole County opportunity is the only concrete solicitation: it seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, and bidders must cover all shipping and delivery costs in their proposals. The Texas RFI is exploratory only—no award, budget, or formal solicitation timeline is set. Without additional opportunities demonstrating actual rimexolone procurement at state or local level, the code shows no actionable market signal for business development professionals focused on pharmaceutical product supply to public health agencies.